Apotex sells global rights to deferiprone to Chiesi Group in carve-out transaction

Apotex Inc. completed the sale of its global rights to deferiprone to Chiesi Farmaceutici S.p.A., an international research-focused healthcare group, by way of a carve-out transaction. Deferiprone is an iron chelator used to treat iron overload conditions resulting from blood transfusions.

Davies Ward Phillips & Vineberg LLP acted as lead transaction and tax counsel to Apotex with a team that included Cameron Rusaw, Steven Cutler and Ha Nguyen (M&A); Elie Roth and Andrew Ellis (tax); Mark Firman (pensions) and Jim Dinning (competition). 

Littler LLP acted as employment counsel to Apotex with a team that included Barry Kuretzky and Tyler Henderson. 

Greenberg Traurig, LLP, acted as U.S. competition counsel to Apotex with a team that included Stephen M. Pepper and Rebecca Rotem.

Chiesi was represented by a team of in-house counsel that included Tiziano Toschi, Mike Gordon and Jonathan Williams. 

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, acted as lead transaction counsel to Chiesi with a team that included Heyward Armstrong, Justin Truesdale, James Jolley and Dave Clement (M&A). 

Baker & McKenzie LLP acted as employment, intellectual property, health regulatory and Canadian tax and competition counsel to Chiesi with a team that included Claire-Marie Colantuoni (employment); Kamleh J. Nicola (intellectual property, health regulatory); Brian Segal and Bryan Horrigan (tax) and Arlan Gates and Sarah Mavula (competition). 

Jones Day acted as U.S. competition counsel to Chiesi with a team that included Ryan Thomas and John Magruder.